Cerebral pseudoatrophy or real atrophy after therapy in multiple sclerosis

Annals of Neurology

Volumn 68, Issue 6, 2010, Pages 778-779

  Samia, Khoury ^a   Rohit, Bakshi ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MARROW TRANSPLANTATION; BRAIN ATROPHY; BRAIN SIZE; CANCER CHEMOTHERAPY; EDITORIAL; GRAY MATTER; MULTIPLE SCLEROSIS; NEUROTOXICITY; PRIORITY JOURNAL; WHITE MATTER;

ATROPHY; BONE MARROW TRANSPLANTATION; CEREBRAL CORTEX; DRUG THERAPY; HUMANS; MULTIPLE SCLEROSIS;

EID: 78650922864     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22254     Document Type: Editorial

References (13)

1. Bermel RA, Bakshi R., The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 2006; 5: 158-170. (Pubitemid 43107851)
2. Zivadinov R, Reder AT, Filippi M, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008; 71: 136-144.
3. Rudick RA., Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis. J Neuroimaging 2004; 14: 54S-64S.
4. Fox RJ, Fisher E, Tkach J, et al. Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications. Mult Scler 2005; 11: 140-145.
5. Frank JA, Richert N, Bash C, et al. Interferon-β-1b slows progression of atrophy in RRMS: three-year follow-up in NAb- and NAb+ patients. Neurology 2004; 62: 719-725.
6. Hardmeier M, Wagenpfeil S, Freitag P, et al. Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. European IFN-1a in Relapsing MS Dose Comparison Trial Study Group. Neurology 2005; 64: 236-240.
7. Dalton CM, Chard DT, Davies GR, et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004; 127: 1101-1107.
8. Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. AFFIRM Investigators. Neurology 2007; 68: 1390-1401.
9. Petzold A, Mondria T, Kuhle J, et al. Evidence for acute neurotoxicity after chemotherapy. Ann Neurol 2010; 68: 806-815.
10. Inglese M, Mancardi GL, Pagani E, et al. Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. Italian GITMO-NEURO Group on Autologous Hematopoietic Stem Cell Transplantation. J Neurol Neurosurg Psychiatry 2004; 75: 643-644.
11. Chen JT, Collins DL, Atkins HL, et al. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology 2006; 66: 1935-1937.
12. Healy BC, Valsasina P, Fillipi M, Bakshi R., Sample size requirements for treatment effects using gray matter, white matter and whole brain volume in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80: 1218-1224.
13. Oh J, Han ET, Lee MC, et al. Multislice brain myelin water fractions at 3T in multiple sclerosis. J Neuroimaging 2007; 17: 156-163.